Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.55 |
| ▸ | THRB | P10828 | 1/20 | 0.55 |
| ▸ | ANO1 | Q5XXA6 | 8/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | ANO2 | Q9NQ90 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6998812 | 0.88 | MAPT (0.55) | MAPTTHRBANO1RAB9AMEN1 | |
| SCHEMBL6992026 | 0.86 | MAPT (0.67) | MAPTTHRBANO1RAB9AMEN1 | |
| SCHEMBL6993062 | 0.83 | MAPT (0.59) | MAPTTHRBANO1RAB9AMEN1 | |
| SCHEMBL7000741 | 0.77 | MAPT (0.67) | MAPTTHRBANO1MEN1KMT2A | |
| SCHEMBL6991198 | 0.76 | MAPT (0.59) | MAPTTHRBANO1RAB9AMEN1 | |
| SCHEMBL7661723 | 0.69 | HDAC1 (0.43) | MAPTRAB9AMEN1KMT2ALMNA | |
| SCHEMBL7217418 | 0.66 | CYP1A2 (0.68) | MAPTTHRBMEN1KMT2ALMNA | |
| SCHEMBL5448456 | 0.66 | NPC1 (0.60) | MAPTRAB9AMEN1KMT2ALMNA | |
| SCHEMBL3211806 | 0.66 | POLB (0.67) | MAPTRAB9AMEN1KMT2ALMNA | |
| SCHEMBL6993898 | 0.66 | PTPN1 (0.54) | MAPTTHRBRAB9AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1016664-B1 | FUSED THIOPHENE COMPOUNDS AND MEDICINAL USE THEREOF | MITSUBISHI PHARMA CORP (JP) | 2003-07-02 | — | — | EP | disclosed |
| US-6455521-B1 | PSYCHOLOGICAL DISORDERS; SIDE EFFECT REDUCTION | MITSUBISHI PHARMA CORPORATION (JP) | 2002-09-24 | — | — | US | disclosed |
| US-20020042411-A1 | Condensed thiophene compounds and pharmaceutical use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2002-04-11 | — | — | US | disclosed |
| US-6271225-B1 | PSYCHOLOGICAL DISORDERS | WELFIDE CORPORATION (JP) | 2001-08-07 | — | — | US | disclosed |
| EP-1016664-A1 | FUSED THIOPHENE COMPOUNDS AND MEDICINAL USE THEREOF | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2000-07-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020042411-A1 | Condensed thiophene compounds and pharmaceutical use thereof | ACIN1, ACHE, TPMT | MAPT 15/4885THRB 1692/4885ANO1 2752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.